Recent 8-K filings for CGTX

• June 4, 2026, 8:00 AM ET other material materiality 0.70 positive item 7.01item 9.01

  Cognition Therapeutics presents at Jefferies; outlines registrational path for DLB psychosis

  Cash ~$31.2M as of March 31, 2026; $25.6M remaining NIA grant funds; runway into Q2 2027.

• May 21, 2026, 7:34 AM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis

  FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20

  Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.

• March 26, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine

  Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.

• March 2, 2026, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting

  Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.

• January 27, 2026, 6:59 PM ET regulatory materiality 0.40 neutral item 8.01item 9.01

  Cognition Therapeutics completes Type C FDA meeting for zervimesine in DLB; discusses Phase 2b endpoints

  Type C meeting with FDA held on Jan 21, 2026 for zervimesine (CT1812) in dementia with Lewy bodies.

• December 18, 2025, 6:59 PM ET other material materiality 0.55 neutral item 1.01item 1.02

  Cognition Therapeutics enters $75M ATM offering with Jefferies, terminates prior $40M ATM

  Entered ATM sales agreement with Jefferies LLC for up to $75M of common stock (December 18, 2025).

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Cognition Therapeutics Q3 net loss narrows to $4.9M; secures $30M offering for zervimesine development

  Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.

• September 15, 2025, 7:59 PM ET other material materiality 0.20 neutral item 8.01item 9.01

  Cognition Therapeutics' investor deck highlights Zervimesine Phase 3 progress

  Presentation focuses on Zervimesine, a once-daily oral therapeutic for neurodegenerative diseases.

• August 28, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Cognition Therapeutics raises ~$30.1M via registered direct offering of 14.7M shares at $2.05/share

  Gross proceeds of $30.1M from sale of 14.7M shares at $2.05/share in a registered direct offering.

• August 26, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

  Cognition Therapeutics regains Nasdaq minimum bid price compliance

  On Aug 26, 2025, Nasdaq confirmed Cognition Therapeutics regained compliance with the $1.00 minimum bid price rule.

• August 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones

  Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.

• June 20, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Cognition Therapeutics shareholders elect two directors, ratify EY as auditor for 2025

  Peggy Wallace re-elected as Class I director with 8,566,458 for, 2,590,981 withheld.

• June 3, 2025, 7:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  Cognition Therapeutics launches expanded access program for zervimesine in DLB

  Anonymous philanthropic donation from family of DLB patient who was in SHIMMER study funds the program.

• June 2, 2025, 7:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Cognition Therapeutics files investor presentation on pathogenic oligomers approach

  Filed investor presentation dated June 2025 under Item 8.01.

• May 8, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial

  Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.

• May 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's

  Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.

• March 20, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Cognition Therapeutics reports 2024 net loss of $34M; highlights positive Phase 2 data for zervimesine

  Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.

• March 12, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 8.01

  Cognition Therapeutics gets Nasdaq extension to Sept 8, 2025; transfer to Capital Market

  Received Nasdaq extension notice on March 12, 2025, granting 180 additional days until Sept 8, 2025 to regain $1.00 minimum bid price.

• February 26, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy

  Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.

• January 28, 2025, 6:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Cognition Therapeutics files corporate presentation; no material new data disclosed

  Company furnished a corporate presentation discussing its focus on targeting pathogenic oligomers for neurodegenerative diseases.

• January 13, 2025, 6:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Cognition Therapeutics files investor presentation with no material updates disclosed

  Filed an investor presentation under Item 7.01 for Regulation FD purposes.

• December 18, 2024, 6:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study

  Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.

• November 13, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group

  Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.

• October 1, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Cognition Therapeutics furnishes investor presentation on amyloid beta oligomer approach

  Presentation titled 'Targeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of CNS Disorders' dated September 2024 made available.

• September 13, 2024, 7:59 PM ET other material materiality 0.75 negative item 3.01

  Cognition Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

  Deficiency letter received on September 12, 2024; stock continues trading under CGTX.

• August 28, 2024, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Cognition Therapeutics furnishes investor presentation with no new material facts disclosed

  Filed an investor presentation under Item 7.01 on August 28, 2024.

• August 8, 2024, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data

  Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.

• July 29, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Cognition Therapeutics files investor presentation on Phase 2 SHINE results for CT1812 Alzheimer's study

  Phase 2 proof-of-concept SHINE study of CT1812 in mild-to-moderate Alzheimer's disease.

• June 7, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Stockholders elect Khattar and Monia as Class III directors at AGM

  Jack A. Khattar elected with 13,573,718 votes for, 2,573,793 withheld, 8,421,943 broker non-votes.

• May 7, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024

  Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.

• March 26, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cognition Therapeutics reports FY2023 net loss of $25.8M, cash runway through May 2025

  Net loss of $25.8M ($0.86 per share) for FY2023 vs $21.4M ($0.91 per share) in FY2022.

• March 13, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  Cognition Therapeutics raises ~$10.4M in public offering of 6.57M shares at $1.75

  Issued 6,571,428 shares of common stock at $1.75 per share; net proceeds ~$10.4M after expenses.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

10 positive 2 negative 21 neutral

source · CGTX on sec.gov